Key facts
- It has raised $29.2M; the latest was Later Stage VC ($13.8M) in Mar 2025.
- Notable investors include Shenzhen Nanshan Strategic Emerging Industry Investment, China V Fund, Wuhan Hi-Tech, Qihang Capital, Shenzhen Lihe Science and Technology Innovation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Forward Pharmaceuticals(China)
- ·The full record, as it builds
Funding rounds
No funding rounds for Forward Pharmaceuticals(China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Forward Pharmaceuticals(China)
Developer of innovative drugs designed for tumors and autoimmunity. The company is dedicated to the research and development of a new generation of small molecule drugs and antibody-targeted drugs, solving the clinical needs of cancer patients around the world.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2015
- Website
- forward-pharm.com/
- Ownership
- Privately Held (backing)
Forward Pharmaceuticals(China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Forward Pharmaceuticals(China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Forward Pharmaceuticals(China) in its N-PORT filings yet. We sweep new filings monthly.